evenfolio

Water & Waste · NSE: IONEXCHANG

ION Exchange (India)

Q2 FY27 earnings and concall highlights

Price as of 16 Nov 2026
311.50−2.43%

Q2 FY27 earnings call · Guided by management

Call held 5 Nov 2026 · Read the filing on NSEFiling

25​%Roha capacity utilisation increase per year · Specialty Chemicals · every yearDutt · Q&A · p. 9
93,700​INR millionBid pipeline · as of September endNaik · p. 4
90​%Legacy project completion · Treatment SolutionsDutt · Q&A · p. 8
10​%UP Jal Jeevan share of total receivables · Treatment SolutionsNaik · Q&A · p. 19
M.Cap
₹4,569Cr
P/E
-140.6×
1Y return
−15.25%
From 52W high
−35.9%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q2 FY27, as filed · consolidated · ₹ Cr

Q2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue675734-8.1%700-3.7%
EBITDA-8568-223.8%32-367.0%
EBITDA margin-12.6%9.3%-2189 bps4.5%-1709 bps
PBTProfit before tax-10868-260.6%7-1650.5%
Net profit-8150-263.6%4-2072.0%
EPS (₹)-6.844.18-263.6%0.35-2054.3%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.

Guidance

Utilisation · Specialty Chemicals · long term25%Roha capacity utilisation planned to grow 25% every year

Treatment Solutions: Treatment Solutions expected to return to its average margin

Indraneel Dutt · Managing Director and CEO · Q&A · p. 8
“So, we should be able to get back to our average margin on the treatment solutions.”

Treatment Solutions: Treatment Solutions margin expected at higher single digits for rest of the year

Indraneel Dutt · Managing Director and CEO · Q&A · p. 9
“We should be able to get to higher single digits in the balance part of the year. That is our expectation.”

Treatment Solutions: Treatment Solutions full-year revenue expected close to previous year's level

Vasant Naik · Group Chief Financial Officer · p. 9
“But having said that, based on the order backlog, the planned execution, and the new Hyundai contract which we are planning to execute, we should be at the end of the year close to the full year levels what we showed in the previous year.”

Engineering: Engineering revenue expected to come close to last year's level after H1 softness

Indraneel Dutt · Managing Director and CEO · Q&A · p. 11
“Yes, so we expect this to go back to that level. As of now, first half has been softer, as my colleague Vasant said. So we are expecting some ramp-up, and we should come close to that number based on what we see now.”

Consumer Products: Consumer Products expected to move towards break-even by end of the year

Indraneel Dutt · Managing Director and CEO · Q&A · p. 17
“While performance in the first half has been marginally below expectations, our current assessment is that the division should move towards break-even by the end of the year.”

In short

  1. 01Q2 operating income was INR 6,747 million, down about 8%, with an EBITDA loss of INR 848 million and net loss of INR 828 million.
  2. 02The quarter was hit by higher cost-to-complete estimates on legacy Treatment Solutions projects, about 90% of the negative PBT; management says the full overrun is now booked.
  3. 03Treatment Solutions revenue is expected to come close to last year's full-year level, with heavy invoicing in Q3 and Q4.
  4. 04Total order book was about INR 29,690 million and bid pipeline INR 93,700 million; Q2 inflow was INR 8,130 million incl. a USD 52.83 million Hyundai order.
  5. 05Specialty Chemicals margins are under pressure from West Asia input costs and Roha plant costs; price increases are better accepted at home than abroad.
  6. 06Roha backward integration plant is under commissioning and expected to be completed by year end.
  7. 07Consumer Products is expected to move towards break-even by the end of the year.
  8. 08New membrane plant in Goa should be up by the end of this financial year, with volumes from next year.

Capex

Specialty Chemicals: Roha backward integration plant under commissioning, completion expected by year end

Vasant Naik · Group Chief Financial Officer · Q&A · p. 20
“As we mentioned, the backward integration plant is presently under commissioning, and we expect that to be completed by the year end.”

Specialty Chemicals: Roha backward integration in final phase; sub-parts being commissioned

Indraneel Dutt · Managing Director and CEO · Q&A · p. 12
“So we are in the final phase, the commissioning of some of the subparts of that plant is going on.”

Industrial Products: Mann+Hummel membrane plant in Goa brownfield expansion to be up by end of this FY

Indraneel Dutt · Managing Director and CEO · Q&A · p. 16
“And that will be manufactured in the brownfield expansion that is coming up next to our current facility in Goa. The plant should be up by the end of this financial year.”

Capex also on modular Ankleshwar expansion and Goa membrane UF facility expansion

Vasant Naik · Group Chief Financial Officer · Q&A · p. 20
“Apart from that, we are doing some modular expansion in our Ankleshwar plant at smaller level, as well as we are doing expansion of our membrane UF facility in Goa.”

Specialty Chemicals: Most capital work in progress relates to the Roha facility

Vasant Naik · Group Chief Financial Officer · Q&A · p. 20
“A large part of the CWIP will be pertaining to the Roha facility.”

Capacity

Specialty Chemicals: Roha resin plant offtake gradually picking up; to add to segment growth

Vasant Naik · Group Chief Financial Officer · p. 5
“Our offtake from our resin manufacturing facility at Roha is gradually picking up, and we expect the facility to contribute to the segment growth in the coming months.”

Specialty Chemicals: Roha plant commissioned 30 September 2025, in operation for about a year

Indraneel Dutt · Managing Director and CEO · Q&A · p. 13
“The plant was commissioned on 30th September 2025, the plant is now in operation for about a year.”

Specialty Chemicals: Roha utilisation being planned to balance volume build-up against achievable pricing

Indraneel Dutt · Managing Director and CEO · Q&A · p. 7
“At the same time, we are carefully planning the utilization of the new Roha facility. Our focus is on balancing the volumes we need to build and the pricing we can achieve, so that we can ramp up the facility at the pace we expect.”

Order book

Engineering: Engineering order book about INR 26,960 million, excluding Sri Lanka and UP Jal Jeevan orders

Vasant Naik · Group Chief Financial Officer · p. 3
“As of September 30th, 2026, our engineering project order book stood at approximately INR 26,960 million excluding the outstanding orders of INR 100 million from the Sri Lanka project and INR 2,630 million under the UP Jal Jeevan order.”

Total order book about INR 29,690 million

Vasant Naik · Group Chief Financial Officer · p. 3
“Our total order book stood at approximately INR 29,690 million.”

Q2 order inflow INR 8,130 million, incl. Hyundai contract of USD 52.83 million

Vasant Naik · Group Chief Financial Officer · p. 4
“During the quarter, the order inflow stood at INR 8,130 million, driven primarily by the medium- sized opportunities and a prestigious international contract from Hyundai Engineering and Construction Company Limited valued at USD 52.83 million.”

Treatment Solutions: Hyundai order is for filtration units in the Middle East with a better margin profile

Vasant Naik · Group Chief Financial Officer · p. 4
“This is for the supply of filtration units in the Middle East with a better margin profile.”

Bid pipeline mainly industrial: refining, power and steel, domestic and international

Indraneel Dutt · Managing Director and CEO · Q&A · p. 7
“So, largely, it is on the industrial side, both in domestic as well as in the international markets. Some of the major industrial sectors contributing to the pipeline are refining segment, power and steel.”

Segments

Treatment Solutions: Treatment Solutions Q2 revenue INR 1,498 million vs INR 2,958 million a year ago

Vasant Naik · Group Chief Financial Officer · p. 4
“Starting with the Treatment Solutions, the segment reported revenue of INR 1,498 million during the second quarter of the current year compared with INR 2,958 million in the corresponding quarter last year.”

Treatment Solutions: Treatment Solutions Q2 EBIT loss INR 1,215 million vs loss of INR 122 million a year ago

Vasant Naik · Group Chief Financial Officer · p. 4
“The EBIT stood at a loss of INR 1,215 million compared with a loss of INR 122 million in Q2 of FY ’25-’26.”

Treatment Solutions: Treatment Solutions H1 revenue INR 3,597 million; EBIT loss INR 1,389 million

Vasant Naik · Group Chief Financial Officer · p. 4
“For the first half of FY 2027, revenue stood at INR 3,597 million compared with INR 4,797 million in the corresponding period last year, while EBIT stood at a loss of INR 1,389 million.”

Treatment Solutions: Treatment Solutions turnover and margins expected to improve in H2

Vasant Naik · Group Chief Financial Officer · p. 4
“Looking ahead, considering our strong order backlog and planned execution schedules, we expect an improvement in turnover during the second half, accompanied by a better margin profile.”

Industrial Products: Industrial Products Q2 revenue up about 35% to INR 1,360 million

Vasant Naik · Group Chief Financial Officer · p. 4
“Revenue increased by approximately 35% year-on-year to INR 1,360 million compared with INR 1,009 million in Q2 of FY ’26.”

Demand

Advanced solutions: Technology and partnerships in place for semiconductor ultra-pure water opportunities

Indraneel Dutt · Managing Director and CEO · Q&A · p. 15
“We have the technology and the required partnerships in place, and we are pursuing opportunities which are commercially attractive for us in that space.”

Industrial Products: Membrane orders coming in from Middle East, Asia-Pacific and Africa

Indraneel Dutt · Managing Director and CEO · Q&A · p. 16
“We are picking up orders in the Middle East, in Asia-Pacific, as well as in Africa.”

International: Wins in Middle East and Africa; trend expected to continue and build overseas backlog

Indraneel Dutt · Managing Director and CEO · p. 22
“We are already seeing some wins coming in, in some markets in Middle East as well as in Africa, and we expect that trend to continue, which should help us build a strong, healthy backlog not only in India but also in overseas markets of our focus areas.”

Specialty Chemicals: Customer response to Roha plant; volumes expected to pick up in coming months

Indraneel Dutt · Managing Director and CEO · Q&A · p. 14
“And we are seeing a decent traction and response from our customers on the Roha plant. So, we believe the volume and the response will pick up even more favorably in the times and months to come.”

Advanced solutions: Several ultra-pure water projects done for solar customers in India and abroad

Indraneel Dutt · Managing Director and CEO · Q&A · p. 15
“We have already done quite a few projects of big capability, capacity, and top customers, both Indian and international, for the solar segment.”

Margins and costs

Specialty Chemicals: Chemicals margins under pressure from West Asia raw material costs and Roha plant costs

Vasant Naik · Group Chief Financial Officer · p. 5
“The margins in this segment continue to remain under pressure due to the input cost inflation arising from the higher RM cost due to the West Asia crisis, along with the facility cost associated with our Roha plant.”

Specialty Chemicals: Cost pass-through to customers gaining success; margins expected to improve in coming months

Vasant Naik · Group Chief Financial Officer · p. 5
“We have taken steps for passing on the cost increases to the customers, and it is now getting increased success, which will reflect in improved margins in the coming months.”

Specialty Chemicals: Chemicals margin hit: Roha about 7%, unrecovered West Asia input costs 7% to 8%

Vasant Naik · Group Chief Financial Officer · Q&A · p. 6
“Coming to the impact of the Roha facility on the segment, it was around 7% at the segment level for this quarter. And as far as the West Asia crisis and the associated increase in input costs which we could not pass on, it is also in the region of 7% to 8%.”

Specialty Chemicals: Around 18% chemicals margin impact from three factors incl. lower exchange gain

Vasant Naik · Group Chief Financial Officer · Q&A · p. 6
“And balance can be attributable to the exchange gain which was at a higher level in the previous year.. So, overall, around 18% can be attributed to these 3 main factors.”

Specialty Chemicals: Price increases better accepted in domestic market, slower in international markets

Indraneel Dutt · Managing Director and CEO · Q&A · p. 6
“We are are seeing progressively better acceptance in the domestic market. In international markets, however, we are seeing slightly slower progress in passing on the price increases.”

Debt and working capital

Treatment Solutions: Jal Jeevan funds trickling in; fund flow expected to pick up

Indraneel Dutt · Managing Director and CEO · Q&A · p. 18
“We are seeing those funds trickling into our projects also. We expect that fund flow to pick up as the weeks and the months go by.”

Treatment Solutions: Jal Jeevan fund flow improved in Q2, but exposure unchanged from March

Vasant Naik · Group Chief Financial Officer · Q&A · p. 19
“There has been some improvement in the 2nd Quarter in terms of the fund flow, but the overall exposure, there is not much of change than what it was in the month of March.”

Unearned revenue rose by around INR 250 crores in the quarter, hitting sales

Vasant Naik · Group Chief Financial Officer · Q&A · p. 20
“As I mentioned, our sales also were impacted because of the increase in the unearned revenue during the quarter, that is around INR 250 crores.”

Customer advances up about INR 50 crores to just under INR 300 crores

Vasant Naik · Group Chief Financial Officer · Q&A · p. 20
“And second is customer advance which has increased by almost around INR 50 crores, and that is around just under INR 300 crores as of the September levels.”

Treatment Solutions: Jal Jeevan dispatches calibrated to funds received

Vasant Naik · Group Chief Financial Officer · Q&A · p. 19
“we are calibrating our dispatches in proportion to the funds what we are receiving.”

Acquisitions and new business

Services: Digital solutions seeing encouraging response; may add to services segment

Vasant Naik · Group Chief Financial Officer · p. 6
“Beyond our core segments, our advanced digital solution offerings are receiving an encouraging response, and we believe this business can contribute positively to our services segment in the coming months.”

Digital: Digital products commercialised after 18 months of investment; sold in India and overseas

Indraneel Dutt · Managing Director and CEO · Q&A · p. 15
“And this is a business that we have been investing in for the last 18 months, and we have now commercialized products, and they are being offered both in India and overseas, and we are seeing very good initial response.”

Oman project is a JV, outside standalone books

Vasant Naik · Group Chief Financial Officer · Q&A · p. 20
“Oman project is a part of a JV in Oman, so that will not form part of our standalone books.”

Management

International: Regional CEOs in place for Americas; Europe CEO joining early January

Indraneel Dutt · Managing Director and CEO · p. 21
“We have now CEOs in place for America's region. For Europe, CEO is joining early January.”

One-offs

Treatment Solutions: Quarter hit by higher cost-to-complete estimates on legacy Treatment Solutions projects

Vasant Naik · Group Chief Financial Officer · p. 3
“The financial performance for the quarter was significantly impacted by changes in the estimated cost to complete of certain legacy projects within the Treatment Solutions segment.”

Treatment Solutions: Entire legacy contract cost overrun booked in this quarter

Indraneel Dutt · Managing Director and CEO · Q&A · p. 8
“We believe that we have got a very good estimate of what that number, and we have considered that entire impact of the overrun in this quarter's financial numbers.”

Treatment Solutions: Legacy overrun is around 90% of the quarter's negative PBT

Indraneel Dutt · Managing Director and CEO · Q&A · p. 8
“And this has actually contributed to around 90 % of this quarter’s negative PBT.”

Treatment Solutions: Some contract revenue reversed under accounting standard to match cost

Vasant Naik · Group Chief Financial Officer · p. 9
“And third is because some of the revenue which we have done on contracts, the same have been reversed under the applicable accounting standard to match the cost..”

Risks

Treatment Solutions: Some GCC dispatches deferred to H2 due to Middle East crisis; high-value execution set for H2

Vasant Naik · Group Chief Financial Officer · p. 4
“Additionally, the execution of some high-value contracts is scheduled for the second half, while certain dispatches to the GCC region have now been deferred to the second half due to the ongoing Middle East crisis.”

Treatment Solutions: Management says legacy contract overrun risk has reached the bottom

Indraneel Dutt · Managing Director and CEO · Q&A · p. 8
“So with that, we believe that the risk on the legacy contracts, from a cost overrun and profitability impact standpoint, that we have been talking for close to about 8 quarters in our calls, we have reached the bottom of the barrel as far as that is concerned.”

Treatment Solutions: No further material adverse impact expected on the legacy contract

Indraneel Dutt · Managing Director and CEO · Q&A · p. 8
“Based on our current assessment, we believe the remaining execution period should not see any further material adverse impact on this contract.”

Specialty Chemicals: Shipping to Europe and Africa unpredictable; a continuing headwind

Indraneel Dutt · Managing Director and CEO · Q&A · p. 12
“We also are seeing that kind of a challenge, especially towards Europe and Africa. We are seeing those shipping lines not being as predictable and consistent as it was in the past.”

Treatment Solutions: Company now selective in picking contracts to avoid legacy-type impact

Indraneel Dutt · Managing Director and CEO · Q&A · p. 19
“We have become very selective in picking up the right contracts. We don't want to end up in a situation of where the legacy contracts, the significant impact will be there.”

Other

Q2 consolidated operating income INR 6,747 million, down about 8% year-on-year

Vasant Naik · Group Chief Financial Officer · p. 3
“During the 2nd quarter, on a consolidated basis, the company reported operating income of INR 6,747 million, decline of approximately 8% year-on-year.”

Q2 EBITDA loss of INR 848 million and net loss of INR 828 million

Vasant Naik · Group Chief Financial Officer · p. 3
“The EBITDA stood at a loss of INR 848 million, while the net loss after tax for the quarter was INR 828 million.”

H1 operating income INR 13,752 million, growth of just under 4%

Vasant Naik · Group Chief Financial Officer · p. 3
“For the first half of FY 2027, the company reported operating income of INR 13,752 million, registering a year-on-year growth of just under 4%.”

H1 EBITDA loss of INR 530 million and net loss of INR 797 million

Vasant Naik · Group Chief Financial Officer · p. 3
“EBITDA stood at a loss of INR 530 million, while the net loss after tax for the period was INR 797 million.”

Specialty Chemicals: Required certification for Roha plant obtained

Indraneel Dutt · Managing Director and CEO · Q&A · p. 14
“So, as we had informed earlier, that the required certification for the Roha plant has been obtained, and we shared that in the last quarter results.”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools